Albany, NY -- (SBWire) -- 08/27/2019 --Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast-2028

1. Diffuse Large B-cell Lymphoma is the most common aggressive subtype of non-Hodgkin Lymphomas, and it affects about 40% of cases globally.
2. Diffuse Large B-cell Lymphoma affects about 7 out of 100,000 people each year. The median age at which the disease occurs is 70.
3. Diffuse Large B-cell Lymphoma incidence in Europe is 3.8/100 000/year, and this increases with age and varies considerably across Europe.

DelveInsight launched a new report on Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast-2028

Key benefits 1. Diffuse Large B-cell Lymphoma market report covers a descriptive overview and comprehensive insight of the Diffuse Large B-cell Lymphoma epidemiology and Diffuse Large B-cell Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Diffuse Large B-cell Lymphoma market report provides insights on the current and emerging therapies.
3. Diffuse Large B-cell Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Diffuse Large B-cell Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diffuse Large B-cell Lymphoma market.

Request for sample pages

"The probability of Diffuse Large B-cell Lymphoma increases with age, from 0.13% and 0.09% before the age of 29 to 1.77% and 1.4% after the age of 70 in men and women, respectively."

Diffuse Large B-cell Lymphoma therapeutics market includes conventional treatment options such as cytotoxic chemotherapeutics (Doxorubicin; Cyclophosphamide; Vincristine and Prednisone) (CHOP) and monoclonal antibody Rituximab (R) which are used as first-line Diffuse Large B-cell Lymphoma treatment in patients. Although R-CHOP is the standard regimen for diffuse large B-cell lymphoma, especially in patients with the germinal centre B-cell (GCB) subtype, yet one-third of patients relapse after therapy. To improve Diffuse Large B-cell Lymphoma treatment outcomes, it is necessary to increase the intensity of regimens or include another drug such as Obinutuzumab or Lenalidomide in the R-CHOP backbone.
Standard treatment for early-stage Diffuse Large B-cell Lymphoma is an abbreviated course of chemotherapy followed by radiotherapy, in case of advanced stage, a full course of chemotherapy is the main treatment with optional radiotherapy. Radiotherapy techniques, like the use of Intensity-modulated radiotherapies (IMRT), have also become generalized recently. In this IMRT era, radiotherapy has become feasible with tolerable toxicity. IMRT is especially effective for treating lesions in the head and neck with acceptable toxicity. At the time of progression or disease relapse, the standard treatment remained is the salvage chemotherapy followed by consolidative Autologous Stem Cell Transplant (ASCT) in chemotherapy-sensitive disease. The benefit of high dose chemotherapy and ASCT rescue in the relapsed disease was originally demonstrated in the pre-rituximab era. However, the vast majority of these patients, are not salvaged by high dose chemotherapy followed by ASCT and will succumb to their disease. Currently, the ongoing efforts are being made to refine treatment in refractory disease based on disease subtype, particularly for patients who are not eligible for a transplant or who have relapsed after transplant.
The parallel development of cellular therapy and bi-specific T-cell engager therapy, which may be agnostic of the cell of origin and molecular features are ongoing. Nevertheless, targeted therapy to Diffuse Large B-cell Lymphoma subtypes will surely play a significant part to tackle the heterogeneity of relapsed/refractory Diffuse Large B-cell Lymphoma successfully. Several randomized trials are being conducted by the companies that are currently researching in this direction to improve outcomes in Diffuse Large B-cell Lymphoma. Many ongoing clinical trials are likely to offer the hope of achieving long-term survival in patients with relapsed or refractory disease. Overall, it will have a major impact on the Diffuse Large B-cell Lymphoma market size in the upcoming years. Additionally, increasing incidence of the disease has also fuelled Diffuse Large B-cell Lymphoma market significantly.

The launch of the emerging therapies is expected to significantly impact the Diffuse Large B-cell Lymphoma treatment scenario in the upcoming years:-

Drugs covered
1. Loncastuximab tesirine
2. Selinexor
3. MOR208
And many others

The key players in Diffuse Large B-cell Lymphoma market are:
1. ADC Therapeutics
2. Celgene
3. Karyopharm Therapeutics
4. MorphoSys
And many others

Table of contents

1. Report Introduction
2. Diffuse Large B-cell Lymphoma Market Overview at a Glance
3. Diffuse Large B-cell Lymphoma Disease Background and Overview
4. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Incident cases of Diffuse Large B-cell Lymphoma (2017-2028)
4.3. Age-Specific cases of Diffuse Large B-cell Lymphoma (2017-2028)
4.4. Gender-Specific cases of Diffuse Large B-cell Lymphoma (2017-2028)
4.5. Stage-specific cases of Diffuse Large B-cell Lymphoma (2017-2028)
4.6. Diagnosed and Treatable cases of Diffuse Large B-cell Lymphoma (2017-2028)
4.7. Acute Lymphoblastic Leukemia Country- Wise Epidemiology
4.8. United States
4.9. EU-5
4.10. Assumptions and Rationale
4.11. Germany
4.12. France
4.13. Italy
4.14. Spain
4.15. United Kingdom
4.16. Japan
5. Diffuse Large B-cell Lymphoma Treatments & Medical Practices
6. Diffuse Large B-cell Lymphoma Marketed Therapies
6.1. Kymriah (Tisagenlecleucel-T): Novartis Pharmaceuticals
6.2. Rituxan Hycela (Rituximab and hyaluronidase human): Genentech
6.3. Yescarta (Axicabtagene ciloleucel): Kite Pharma
7. Diffuse Large B-cell Lymphoma Emerging Therapies
8. Key Cross Competition
8.1. MOR208: MorphoSys
8.2. Selinexor: Karyopharm Therapeutics
8.3. Loncastuximab tesirine: ADC Therapeutics
9. Diffuse Large B-cell Lymphoma Market Size
10. 7MM Acute Lymphoblastic Leukemia: Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Diffuse Large B-cell Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight